53123-88-9 | Rapamycin

Chemical type

• Autophagy activator

^[1]

• mTOR inhibitor (Macrolide compound)

^[2]

Key properties

• mTOR inhibitor
• Activates autophagic efflux (increases LC3-I to LC3-II conversion)
• Downregulates RDH5 protein by enhancing degradation
• Decreases SQSTM1/P62 levels

^[1]

• Inhibits the mTOR signaling pathway. In this study, it was shown to counteract the negative effects of glucocorticoids on the intestinal barrier by downregulating Ddit4 expression and modulating the transcriptomic impact of the glucocorticoid receptor, thus protecting against epithelial antiproliferative actions.

^[2]

• Induces autophagy in RPE cells
• Studies regulation of visual cycle protein stability

^[1]

• Used experimentally to attenuate the harmful effects of prednisolone on intestinal barrier function, such as reducing bacterial translocation and early rectal bleeding in a colitis model.

^[2]

Classification by use

• Chemicals used as immunosuppressants (original)
• Chemicals used as autophagy inducers in research

^[1]

• Experimental barrier-protective agent

^[2]

A trustworthy factory and manufacturer

1. [Cite:1] HSP90 stabilizes visual cycle retinol dehydrogenase 5 in the endoplasmic reticulum by inhibiting its degradation during autophagy, JBC, Volume 301, Issue 2, February 2025, 108126
2. [Cite:2] Rapamycin and parenteral administration attenuate the harmful effects of glucocorticoids on the intestinal barrier function, Biomedicine & Pharmacotherapy, Volume 193, December 2025, 118721